Fig. 1
From: Efficacy and safety of tepotinib in MET‑altered non‑small cell lung cancer: a meta-analysis
PRISMA flow chart of study selection process.
Fig. 1 | Scientific Reports
From: Efficacy and safety of tepotinib in MET‑altered non‑small cell lung cancer: a meta-analysis
PRISMA flow chart of study selection process.
